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OBJECTIVE: To evaluate the long-term cost-effectiveness of different strategies for human papillomavirus (HPV) DNA testing combined
with Pap smear for cervical cancer screening in Taiwan.
METHODS: This study adopts a perspective of Department of Health in cost-effectiveness analysis to compare a no-screening strategy
with nine different screening strategies. These strategies comprise three screening tools (Pap smear alone, HPV DNA testing
followed by Pap smear triage, and HPV DNA testing combined with Pap smear), and three screening intervals (annually, every
3 years, and every 5 years). Outcomes are life expectancy, quality-adjusted life years (QALYs), lifetime costs, and incremental cost-
effectiveness ratios (ICERs). Probabilistic sensitivity analyses (PSAs) were conducted to assess parameter uncertainty.
RESULTS: When three times gross domestic product per capita is used as the decision threshold, all nine screening strategies were
cost-effective compared with the no-screening strategy. Compared with the current screening strategy (an annual Pap smear), HPV
DNA testing followed by Pap smear triage every 5 years and every 3 years were cost-effective. Results of PSA also indicated that a
HPV DNA testing followed by Pap smear triage every 5 or every 3 years achieved the highest expected net benefits.
CONCLUSIONS: Possible economic advantages are associated with extending the cervical cancer screening interval from one Pap smear
annually to HPV DNA testing followed by Pap smear triage every 5 years with an ICER $1247000 per QALY gained, especially in a
country with a publicly financed health-care system.
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Cervical cancer is one of the most common cancers in Taiwan,
currently ranked as the fifth leading cancer causing death for
females (Chen et al, 2009). Although the incidence and mortality
associated with cervical cancer have declined steadily since the
National Health Insurance (NHI) program was instituted in 1995,
the incidence of cervical cancer in Taiwan is still one of the highest
in Asia and is a huge burden to the health-care system.
All females in Taiwan aged X30 years are now provided with a
free Pap smear annually by the NHI system (Koong et al, 2006).
The annual Pap smear screening rate for females aged 30–69 years
increased to 27.4% in 2007 from 14.3% in 1996. The 3-year
coverage rate reached 52.4% during 2005–2007; 5-year coverage
was roughly 60% during 2003–2007 (Bureau of Health Promotion,
2007). In France, 60% of the female population had a regular
Pap smear within the last 3 years (Schaffer et al, 2000), 80% of
Dutch females and 85% of English females had a Pap smear within
the last 5 years (Patnick, 2000; Van Ballegooijen and Hermens,
2000). Notably, the screening program in Taiwan has not yet
achieved satisfactory coverage. The health authorities in Taiwan
currently face the challenge of implementing cervical cancer
screening programs with increased effectiveness.
A population-based randomised trial conducted in Sweden
indicated that primary the human papillomavirus (HPV) DNA
testing with Pap smear triage and repeat HPV DNA testing for
those who test positive in HPV DNA testing with negative Pap
smear results were the most effective cervical cancer screening
strategy (Naucler et al, 2009). Recent findings from a cohort study
on long-term outcomes of HPV infection in Taiwan demonstrated
that, for a female who had a normal Pap smear result, the 6-year
cumulative risk of developing high-grade squamous intraepithelial
lesions (HSILs) was 10.0% when the HPV DNA testing result was
positive, whereas the risk for those with negative HPV DNA testing
was only 0.34%. These data support the efficacy of HPV DNA
testing for cervical cancer screening program with intervals of at
least 5 years (Huang et al, 2008). Another European study of six
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scountries also suggested that screening intervals could safely be
lengthened to 6 years among females with a negative HPV DNA
testing result (Dillner et al, 2008).
In two systematic review studies, Holmes et al (2005) and
Muhlberger et al (2008) summarised existing evidence for the cost-
effectiveness of incorporating the HPV DNA testing into current
cervical cancer screening programs. Their analytical results
showed the HPV DNA testing with a Pap smear as a screening
strategy for females aged X30 years was cost-effective. With an
incremental cost-effectiveness ratio (ICER) threshold of h50000
per quality-adjusted life year (QALY), Muhlberger et al (2008)
concluded that, in comparison with annual Pap smear, or Pap
smear every 2, 3, or 5 years, the probabilities of HPV DNA
testing strategies being cost-effective were 83, 25, 55, and 92%,
respectively. These analytical findings illustrate that when
evaluating the cost-effectiveness of the HPV DNA testing, the
screening interval should be considered.
Several studies utilised computer-based models to estimate the
cost-effectiveness of adding the HPV DNA testing to current
cervical cancer screening programs in Sweden, Canada, the United
States, the United Kingdom, the Netherlands, France, Italy, and
Germany. Adding the HPV DNA testing can reduce cancer
incidence and is less costly than Pap smear alone (Mandelblatt
et al, 2002b; Mittendorf et al, 2003; Goldie et al, 2004; Kim et al,
2005; Bistoletti et al, 2008; Chuck, 2009).
In Taiwan, which has a poor Pap smear participation rate, policy
makers face the problems of whether to combine the HPV DNA
testing with Pap smear for cervical cancer screening and
determining the optimal screening interval. This study evaluates
the long-term cost-effectiveness of different strategies for HPV
DNA testing combined with Pap smear for cervical cancer
screening in Taiwan for healthy females aged 30 years.
MATERIALS AND METHODS
Cost-effectiveness analysis and decision analytic model
This cost-effectiveness analysis (CEA) adopts the perspective of
Department of Health. A decision analytic model was developed
using TreeAge Pro Suite 2009 software (TreeAge Software, Inc.,
Williamstown, MA, USA) for evaluating the long-term costs and
effectiveness of various cervical cancer screening strategies. This
study used clinical outcome measures, including cervical cancer
incidence, mortality, life expectancy, and QALYs. All costs, life
expectancy, and QALYs were discounted to their present values at
an annual rate of 3%. The ICERs were calculated as the difference
in cost divided by the difference in QALYs for each strategy
compared with the no-screening strategy, with the strategy of an
annual Pap smear, or with the next-best strategy. Currently, no
consensus exists for a specific cost-effectiveness threshold in
Taiwan. However, this study considered strategies with ICER
values less than three times per capita gross domestic product
(GDP) as cost-effective (Eichler et al, 2004). In 2008, Taiwan’s
per capita GDP was NT$538790 (Directorate-General of Budget,
Accounting and Statistics, 2009a). Therefore, the cost-effectiveness
threshold assumed in this model was NT$1620000/QALY.
Natural history model
The natural history model for cervical cancer was adopted from
literature (Debicki et al, 2008; Rogoza et al, 2008; Sua ´rez et al,
2008). The health states of the decision analytic model for the
natural history of cervical cancer among females have the
following seven categories: normal (healthy); HPV infection;
grades of cervical intraepithelial neoplasia (CIN) (CIN I, CIN II
or III); persistent CIN II or III; stage of cervical cancer; death from
other causes; and, death from cervical cancer. This model
simulates a cohort of 30-year-old healthy females; the hypothetical
cohort moves between different health states according to
prespecified probabilities in each Markov cycle (1 year). The
analytical time horizon was lifetime (85 years old).
The model starts with a cohort of 30-year-old healthy females
(normal state). During simulation, individuals may remain in the
normal state or progress to the HPV infection state in the next year
(or cycle). Individuals with HPV infection may remain in the HPV
infection state, regress to the normal state, or progress towards the
CIN I state. The CIN I patients may remain in the CIN I state,
regress to the normal state, or progress towards the CIN II or III
state. The CIN II or III patients may remain in the CIN II or III
state, regress to the normal state, or progress towards the persis-
tent CIN II or III state. From there, patients may remain in
the persistent CIN II or III state, regress to the normal state, or
progress towards the cervical cancer state. When individuals reach
the cervical cancer state, we assume no regression is possible; that
is, they can only progress to a cured cancer state when alive at 5
years after diagnosis or to the cervical cancer death state. In this
model, a female in any state can die because of other causes.
Screening strategies
This study was designed to compare a no-screening strategy
with nine different screening strategies, which varied using
three different screening algorithms – Pap smear alone, HPV
DNA testing followed by Pap smear triage, and HPV DNA testing
combined with Pap smear, with three screening intervals –
annually, every 3 years, and every 5 years. We assume the ceiling
age for screening is 69 years.
Table 1 lists the primary screening and triage tool, screening
ages, screening interval, and coverage for each strategy. We
assume a 30% coverage rate for annual screening, based on the
reported 28.4% of females aged 30–69 years who had a Pap smear
in 2007. Similarly, 3-year (60%) and 5-year coverage rates (75%)
were assumed as the reported percentages of 52.5% and 64.9% of
those who underwent at least one Pap smear during a 3- or
5-year period, respectively.
When a female is invited to undergo cervical cancer screening,
she is stratified into the never-screened or regularly screened
categories (Figure 1). According to research by Chen et al (2009),
after implementing the screening program in 1995, roughly 75%
eligible females in Taiwan participated in the program at least once
by 2007. We infer that the percentage of those never screened was
25%. Considering the uncertainty, 12% and 30% as low and high
estimate values were changed during sensitivity analysis.
In the regular screening strata, a female may or may not be
willing to participate in an appropriate year. If a female chooses to
undergo screening, the following three combinations of screening
tools were evaluated: (1) Pap smear as the primary screening test
followed by colposcopy-guided biopsy for positive Pap smear
results (i.e., Pap); (2) HPV DNA testing as the primary screening
test, using a Pap smear as a triage strategy for those who test
positive for high-risk HPV types in HPV DNA testing (i.e., HPV-
Pap); and, (3) HPV DNA testing in combination with Pap smear as
the primary screening test, using a Pap smear as a follow-up
screening strategy for those who have positive Pap smear results or
test positive for high-risk HPV types (i.e., combination).
Experts and existing guidelines were consulted before making the
following assumptions for management of females with different
screening results: (1) women with negative primary screening results
are asked to undergo regular screening; (2) when a woman had a
positive final screening result, she is urged to undergo a colposcopy-
guided biopsy. All women with a confirmed histology of CIN I,
CIN II or III and cancer are assumed to be treated with the therapy
recommended by the Taiwan Cooperative Oncology Group (Taiwan
Cooperative Oncology Group, 2007). These patients are assumed
treated immediately after disease confirmation. When treatment was
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scompleted, annual Pap smear screening followed; (3) in the HPV-Pap
and combination strategies, those negative after follow-up screenings
are suggested to undergo annual Pap smear screening for the rest of
their lifetime.
We further assume that compliance with follow-up and
treatment is 100% in the model.
Model parameters
Table 2 summarises the probabilities, costs, and data sources used
in the base-case analysis.
Parameters of the natural history model Parameters of HPV
infection rates and disease transitions were obtained from the study
by Debicki et al (2008). They estimated disease parameters by
reviewing published reports of Taiwanese screening coverage and
cancer incidence, and further calibrated disease parameters to fit
cervical endpoints. The succinct model, which adopted fewer complex
processes and a short cycle length of 1 year, was used in this study.
Survival rate and death probability The annual probabilities of
dying from cervical cancer for patients were obtained from
survival rates published by the Taiwan Cancer Registry (2007).
The 1-, 2-, 3-, 4-, and 5-year survival for patients with invasive
cervical cancer (all stages) in Taiwan were 90.4, 83.2, 79.4, 76.7, and
74.8%, respectively.
Age-specific other-cause mortality was obtained from the
2007 Life Table for Taiwan’s female population (Department
of Statistics, 2008). For example, the probability of dying, which
increases with age, was 0.00055 for those aged 30 and 1 for those
aged 85.
Screening test characteristics Test sensitivity was defined as a
positive screening result for patients with CIN I or worse in this
model. Test specificity was defined as a negative result for females
in the normal state. Screening test characteristics used were
obtained from and Mayrand et al (2007). Mayrand et al conducted
a randomised trial comparing the sensitivity and specificity of the
HPV DNA testing and Pap smear for females aged 30–69 years in
Canada (n¼10154). This study used Pap smear sensitivity for CIN
II or III of 55.4% (95% CI¼33.6–77.2%), and a specificity of
96.8% (95% CI¼96.3–97.3%). Arbyn et al conducted meta-
analyses of clinical applications of the HPV DNA testing. Their
analytical results indicated that sensitivity of the HPV DNA testing
(89.5%; 85.1–93.1%) or the combination of the HPV DNA testing
with Pap smear (99.2%; 97.4–100.0%) are higher than Pap
smear alone in other studies for detecting CIN II cases or
worse. The specificity was 87.5% (95% CI ¼ 85.0–89.9%) for
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Figure 1 Screening decision tree showing different screening tests at three screening intervals and follow-up management.
Table 1 Cervical cancer primary screening and follow-up tool, screening ages, screening interval, and coverage for each strategy
Screening
strategy
a Primary screening
Follow-up
screening
b
Screening ages,
year
Screening interval,
year
Coverage,
%
c
Pap, 1-y Pap smear — 30–69 1 year 30.0 (27.4–50.0)
Pap, 3-y Pap smear — 3 year 60.0 (52.4–65.0)
Pap, 5-y Pap smear — 5 year 75.0 (70.0–75.0)
HPV-Pap, 1-y HPV DNA testing Pap smear 1 year 30.0 (27.4–50.0)
HPV-Pap, 3-y HPV DNA testing Pap smear 3 year 60.0 (52.4–65.0)
HPV-Pap, 5-y HPV DNA testing Pap smear 5 year 75.0 (70.0–75.0)
Combination, 1-y Combine HPV DNA testing with Pap smear Repeat Pap smear 1 year 30.0 (27.4–50.0)
Combination, 3-y Combine HPV DNA testing with Pap smear Repeat Pap smear 3 year 60.0 (52.4–65.0)
Combination, 5-y Combine HPV DNA testing with Pap smear Repeat Pap smear 5 year 75.0 (70.0–75.0)
Abbreviation: HPV¼human papillomavirus.
a‘Pap’ refers to Pap smear as primary screening test follows by colposcopy-guided biopsy for positive Pap smear results. ‘HPV-Pap’
refers to HPV DNA testing as primary screening test, using Pap smear as a triage strategy for those who test positive for high-risk HPV types in HPV DNA testing results.
‘Combination’ refers to HPV DNA testing in combination with Pap smear as primary screening test, using Pap smear as a follow-up screening strategy for those who have Pap
smear results or test positive for high-risk HPV types. ‘1-y’, ‘3-y’, and ‘5-y’ refer to a 1-year, 3-year, and 5-year screening intervals for women 30–69 years of age, respectively.
bFollow-up of positive primary screening results.
c1-year, 3-year, and 5-year coverage rates were assumed as the reported percentages of those who underwent at least one Pap
smear during 2007, 2005–2007, or 2003–2007 period.
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sthe HPV DNA testing and 87.3% (95% CI¼87.3–90.4%) for the
combination test.
Utility weight data The health utility data for the base case and
ranges were adopted from a CEA evaluating HPV vaccination
programs in Taiwan (Sua ´rez et al, 2008), which was compiled
using health utility data collected in the USA (Insinga et al, 2007).
Costs data From a perspective of Department of Health,
only costs associated with direct medical costs were utilised.
Furthermore, this study included only the direct medical costs
associated with use of health-care services covered by the NHI
program.
The category for costs associated with cervical cancer consists of
costs of screening tests, costs of diagnosis, costs of treatment for
CIN I, CIN II or III, and cancer treatment costs.
Screening costs Pap smear screening as a procedure for cervical
cancer prevention includes: (1) Pap smear sampling, (2)
pelvic examination, and (3) Pap smear cytological examination.
Table 2 Model parameters of the decision analytic model for cervical cancer
Model parameter Base case Range Reference
Natural history
Normal to HPV 0.06 0–0.17 Debicki et al (2008);
HPV to CIN I 0.049 0.028–0.07 Rogoza et al (2008);
CIN I to II/III 0.091 0.08–0.30 Sua ´rez et al (2008)
CIN II/III to persistent CIN II/III 0.114 0–0.114
Persistent CIN II/III to cancer 0.05 0–0.10
HPV regression 0.516 0.435–0.87
CIN I regression 0.449 0.31–0.54
CIN II/III regression 0.227 0.04–0.227
5-year survival rate from cervical cancer, %
1-year 90.4 85.4–95.4 Taiwan Cancer Registry (2007)
2-year 83.2 78.2–88.2
3-year 79.4 74.4–84.4
4-year 76.7 71.7–81.7
5-year 74.8 69.8–79.8
Test characteristics, %
a
Sensitivity of Pap smear 55.4 33.6–77.2 Mayrand et al (2007)
Sensitivity of HPV DNA testing 89.5 85.1–93.1 Arbyn et al (2006)
Sensitivity of Pap smear and HPV DNA testing 99.2 97.4–100 Arbyn et al (2006)
Specificity of Pap smear 96.8 96.3–97.3 Mayrand et al (2007)
Specificity of HPV DNA testing 87.5 85.0–89.9 Arbyn et al (2006)
Specificity of Pap smear and HPV DNA testing 87.3 87.3–90.4 Arbyn et al (2006)
Utility value (6-month)
Normal population 1.00 1.00 Sua ´rez et al (2008)
HPV 1.00 0.99–1.00
CIN I 0.96 0.92–0.99
CIN II/III 0.96 0.92–0.99
Treated cancer 0.73 0.58–0.87
Cured/follow-up cancer 0.94 0.62–0.97
Direct medical costs, NT$
b,c
Screening test, NT$
Pap smear
d 430.0 BNHI (2009)
HPV DNA testing 600.0 Market price
HPV DNA testing and Pap smear 1030.0
Diagnosis costs, NT$
Repeat Pap smear
e 440.0 BNHI (2009)
Colposcopy (with biopsy) 2183.0 Debicki et al (2008)
Treatment costs, NT$
CIN I 2347.0 Tang et al (2010)
CIN II/III 6956.0
1st year of cervical cancer 232389.0
2nd year of cervical cancer 123250.0
3rd year of cervical cancer 167009.0
4th year of cervical cancer 95645.0
5th year of cervical cancer 113627.0
Abbreviations: CIN¼cervical intraepithelial neoplasia; HPV¼human papillomavirus; NHI¼National Health Insurance.
aSensitivity was defined as a screening positive result for
patients with CIN I or worse in this model. Specificity was defined as a negative result for women in normal state.
bRange between  50% and +50% of the base-case value unless
otherwise indicated.
cDirect medical costs were the costs associated with the use of health-care services covered by the NHI program.
dPap smear screening procedures were
(1) Pap smear sampling, (2) a pelvic examination, and (3) Pap smear cytological examination. Health-care providers are reimbursed NT$430 by the NHI system for these
services.
eThe procedures for a repeated Pap smear are (1) vaginal irrigation, (2) a pelvic examination, (3) obtaining a Pap smear sample, and (4) a Pap smear cytological
examination. Health-care providers are reimbursed NT$440 by the NHI system for these services.
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sHealth-care providers are reimbursed NT$430 by the NHI system
for these services (Bureau of National Health Insurance, 2009).
Additionally, the average price of the HPV DNA testing is assumed
to be NT$600.
Diagnostic costs For the HPV-Pap and combination strategies,
patients who had a positive primary screening test underwent
another Pap smear test. The procedures for a repeated Pap smear
are (1) vaginal irrigation, (2) pelvic examination, (3) obtaining Pap
smear sample, and (4) Pap smear cytological examination. Health-
care providers are reimbursed NT$440 by the NHI system for these
services (Bureau of National Health Insurance, 2009). Those who
had a positive primary screening test with the Pap strategy, or had
a positive final screening result with the HPV-Pap or combination
strategy, or have been with cervical cancer or precancerous lesion,
are referred to take a colposcopy-guided biopsy. Diagnostic cost of
the colposcopy-guided biopsy was NT$2183 (Debicki et al, 2008).
Treatment costs Direct medical costs for precancerous lesions
and cervical cancer treatments in Taiwan were obtained from the
study by Tang et al (2010). All costs are reported in New Taiwan
Dollars (in this study, US$1.00¼NT$33.032).
Sensitivity analysis
Considering uncertainty is crucial in a decision analytical study.
To better understand the impact on the results for different levels
of participation, along with the purpose to present the validity of
the model results, a scenario sensitivity analysis was performed by
approximating the highest coverage rate at 100% for all screening
intervals. Probabilistic sensitivity analyses (PSAs) were conducted
to assess parameter uncertainty. The ranges of parameters were
mostly from published studies (Table 2). A 50% increase or
decrease in the base-case value for costs data were changed during
sensitivity analysis.
Probability distributions were defined for the following six sets
of model parameters: (1) screening rate; (2) disease transition
probabilities in the natural history model; (3) survival rate for
cervical cancer; (4) test characteristics; (5) utility; and, (6) costs.
A beta distribution was fitted for screening rate, the natural history
model, survival rate for cervical cancer, test characteristics, and
utility, those parameters were between 0 and 1. A gamma
distribution can be used to represent uncertainty in cost data,
which was constrained to be non-negative and characterised in the
interval of 0 to positive infinity (Briggs et al, 2007).
The PSA results in this model were analysed using cost-
effectiveness acceptability frontier (CEAF) constructed from
cost-effectiveness acceptability curves (CEACs) for the different
strategies. The CEACs were calculated from net monetary benefit
over a range of willingness-to-pay (WTP) thresholds for each
strategy, and produced by plotting the probability of being cost-
effective for a strategy under different WTP thresholds (Barton
et al, 2008). To further determine the uncertainty associated with a
priori intervention over all WTP thresholds for each strategy
(Fenwick et al, 2001), this study produced a CEAF by identifying
the probability of the optimal strategy in each of 1000 iterations
based on the strategy with the highest expected net benefits at
different WTP thresholds (Barton et al, 2008).
RESULTS
Base-case analysis
Table 3 presents the lifetime effectiveness and costs for a
hypothetical cohort of 30-year-old females for all nine screening
strategies. Predicted effectiveness outcomes were lifetime inci-
dence and mortality for cervical cancer, total life expectancy, and
total QALYs; additionally, total lifetime costs, and ICERs calculated
by comparing different bases (i.e., the no-screening strategy, Pap
annual strategy, and next-best strategy) are presented.
Reduction in lifetime risk Compared with the no-screening
strategy, all nine screening strategies were more effective (Table 3).
The estimated reduction in lifetime incidence and related morta-
lity for cervical cancer when screened at 30 years of age varies at
35.8–71.1%, depending on screening tests, screening intervals, and
screening strategies. The HPV-Pap and combination strategies at
annual, 3-, or 5-year intervals prevented more cases than the Pap
strategy at annual, 3-, or 5-year screening intervals. The model
estimated cervical cancer cases at 87.6–118.2 per 100000 women
and a related mortality of 25.6–34.8 per 100000 patients with the
Pap strategy; 54.6–70.0 cases and 16.3–20.7 deaths for the HPV-
Pap strategy; and 53.2–65.2 cases and 15.9–19.3 deaths with the
combination strategy (Table 3).
Cost-effectiveness analysis Figure 2 presents the cost-effective-
ness results that indicate that all nine screening strategies
Table 3 Total life expectancy, total QALYs, total lifetime costs, and ICERs of all alternatives screening strategies in health care perspective
Screening
strategy
a
Cancer
cases,
per 10
5
Death of
cancer,
per 10
5
Total
undiscounted
life expectancy
Total life
expectancy
b
Total
undiscounted
QALYs
Total
QALYs
b
Total undiscounted
lifetime
costs, NT$
Total
lifetime costs,
NT$
b
ICER,
NT$/QALYs
c
ICER,
NT$/
QALYs
d
ICER,
NT$/
QALYs
e
No screening 184.1 55.0 49.3586 25.5699 49.3339 25.5583 999 425 — — —
Pap, 5-y 118.2 34.8 49.3629 25.5713 49.3416 25.5612 4700 2352 659966 659966 Less costly but
less effective
Pap, 3-y 102.9 30.2 49.3638 25.5716 49.3436 25.5620 6057 3045 708189 888718 Less costly but
less effective
Pap, 1-y 87.6 25.6 49.3648 25.5719 49.3458 25.5629 8355 4242 837171 Extended dominance —
HPV-Pap, 5-y 70.0 20.7 49.3655 25.5721 49.3480 25.5636 11084 5202 896360 1323497 1246883
Combination, 5-y 65.2 19.3 49.3658 25.5723 49.3487 25.5639 12457 6088 1009501 Extended dominance 1757905
HPV-Pap, 3-y 60.0 17.8 49.3661 25.5724 49.3499 25.5644 13149 6261 955254 1357692 1302645
Combination, 3-y 57.1 16.9 49.3663 25.5724 49.3501 25.5645 14700 7301 1103724 Extended dominance 1831557
HPV-Pap, 1-y 54.6 16.3 49.3664 25.5725 49.3506 25.5647 15377 7507 1101369 3891250 1745615
Combination, 1-y 53.2 15.9 49.3665 25.5725 49.3509 25.5648 17031 8696 1262840 9915000 2238241
Abbreviations: ICER¼incremental cost-effectiveness ratio; QALY¼quality-adjusted life year.
aPap refers to Pap smear as the primary screening test followed by colposcopy-
guided biopsy for positive Pap smear results. HPV-Pap refers to HPV DNA testing as the primary screening test, using a Pap smear as a triage strategy for those who test positive
for high-risk HPV types in HPV DNA testing. Combination refers to HPV DNA testing in combination with Pap smear as the primary screening test, using a Pap smear as a follow-
up screening strategy for those who have positive Pap smear results or test positive for high-risk HPV types. 1-y, 3-y, and 5-y refer to three screening intervals of annually, every 3
years, and every 5 years for women 30–69 years of age, respectively.
bLife expectancy, QALYs, and costs are discounted at 3% per annum.
cCost-effectiveness ratio calculated as
the difference in cost divided by the difference in QALYs for each strategy compared with the no screening strategy.
dCost-effectiveness ratio calculated as the difference in cost
divided by the difference in QALYs for each strategy compared with next best strategy.
eCost-effectiveness ratio calculated as the difference in cost divided by the difference in
QALYs for each strategy compared with annual Pap smear alone strategy.
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sgenerated greater effectiveness (i.e., total QALYs) and total costs
than the no-screening strategy from the perspective of Department
of Health. Using three times Taiwan’s per capita GDP as the cost-
effectiveness threshold, all these strategies were cost-effective.
However, when each strategy compared with the next most-
effective non-dominated strategy, an annual Pap, combination
every 5 years and every 3 years were extended-dominated. Pap
every 5 years and every 3 years, HPV-Pap every 5 years and every
3 years had ICERs of NT$660000, NT$889000, NT$1323000,
NT$1358000 per QALY gained, respectively. These strategies were
cost-effective at three times per capita GDP threshold.
If the current screening strategy, an annual Pap, is used for
comparison, HPV-Pap every 3 years and every 5 years cost
NT$1303000 and NT$1247000 per QALY gained, respectively.
These strategies are oNT$1620000/QALY. However, extending
screening intervals for Pap annually to every 3 or 5 years was less
costly but also less effective. Changing Pap annually to every 3 or 5
years save NT$1197 to NT$1890 while loss 0.33–0.62 of discounted
quality-adjusted life days per woman (see Table 3 and Figure 2).
Sensitivity analysis
The coverage rate changes into 100% for all screening intervals in
the scenario sensitivity analysis. Results show that screening
strategies on the sensitivity analysis efficiency frontier in this
analysis are Pap every 5 years and 3 years, HPV-Pap every 5 years,
every 3 years and annually, and combination annually (Figure 3).
The ranking, and the magnitude of the discounted QALYs and
costs, of the alternatives are as expected (i.e., programs with the
annual screening are the most efficacious and the most costly),
suggesting the validity of this model.
The PSA results are presented in a CEAF. The CEAF was plotted
by presenting the optimal strategy under different WTP thresholds
(Figure 4). When three times GDP per capita is used as the
decision threshold, the annual Pap strategy (oNT$207000), the
annual HPV-Pap strategy (NT$207000–351000), the Pap strategy
every 5 years (NT$351000–594000), the HPV-Pap strategy every 5
years (NT$594000–1413000), and the HPV-Pap strategy every 3
years (XNT$1413000) achieved the highest expected net benefits.
DISCUSSION
Screening has proven cost-effective in preventing cervical cancer
according to many studies conducted in different countries
(Mandelblatt et al, 2002a,b; Mittendorf et al, 2003; Goldie et al,
2004, 2005; Kim et al, 2004, 2005; Holmes et al, 2005; Siebert et al,
2006; Anderson et al, 2008; Andres-Gamboa et al, 2008; Bistoletti
et al, 2008; Muhlberger et al, 2008; Chuck, 2009; Vijayaraghavan
et al, 2009); the model results in this study demonstrate the cost-
effectiveness of screening compared with that of a no-screening
strategy, regardless of which screening tool or interval is used.
Compared with the annual Pap strategy, the HPV-Pap strategy at
3- or 5-year intervals are cost-effective. Annual HPV-Pap strategy,
combination strategy annually or at 3- or 5-year intervals gene-
rated the greatest effectiveness, while cost a substantial amount of
total costs; thus, the annual HPV-Pap and the combination
strategies are not cost-effective. For a nation with a publicly
financed health-care system, such as Taiwan, this study shows that
extending cervical cancer screening interval from Pap annually to
HPV-Pap strategy every 3 or 5 years costs NT$1303000 or
NT$1247000 per QALY gained, respectively.
Compared with the no-screening strategy, Pap annually and Pap
every 3 and 5 years reduced the incidence of cervical cancer in a
lifetime by 52.4, 44.1, and 35.8% under the coverage assumptions
in this model. Arbyn et al (2006) and Mayrand et al (2007)
indicated that the HPV DNA testing has greater sensitivity and is
more accurate than Pap smear for detecting HSILs. As expected,
analytical results demonstrate that the HPV-Pap or combination
strategy annually or at 3- or 5-year screening intervals prevented
more cases than the Pap strategy annually or at 3- or 5-year
screening intervals. The reductions in lifetime incidence of cervical
cancer with the HPV-Pap strategy annually or at 3- or 5-year
screening intervals were 70.3, 67.4, and 62.0%; the values for
the combination strategy were 71.1% (annually), 69.0% (every
3 years), and 64.6% (every 5 years). Two studies undertaken in the
United States reported a decline in lifetime incidence of cervical
cancer of 70–87% (Mandelblatt et al, 2002b) and 81–90% (Goldie
et al, 2004) for Pap smear alone with different screening intervals.
The HPV DNA testing with a Pap smear in a cervical cancer
screening program decreased risk by 78–93% (Mandelblatt et al,
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CEA of HPV DNA testing and Pap smear in Taiwan
I H-I Chow et al
1778
British Journal of Cancer (2010) 103(12), 1773–1782 & 2010 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s2002b) and 90–93% (Goldie et al, 2004). This study identified an
increasing trend of a reduction in the incidence of cervical cancer
that is consistent with findings obtained with other models
comparing the HPV DNA testing with Pap smear alone.
Several studies demonstrated that using the HPV DNA testing as
primary screening or combined with Pap smear with a screening
interval of every 2, 3, or 5 years was more cost-effective than Pap
smear alone (Mandelblatt et al, 2002b; Mittendorf et al, 2003;
Goldie et al, 2004; Kim et al, 2005; Bistoletti et al, 2008; Chuck,
2009). Analytical results in this study demonstrate that the
HPV-Pap strategy at 3- or 5-year intervals was cost-effective; this
finding is generally consistent with those studies. However, the
results of this model demonstrate that the combination strategy,
regardless of screening intervals, were not cost-effective compared
with current cervical cancer screening program (Pap annually).
Three important factors were considered in this study. First, the
combination strategy annually and at 3- and 5-year intervals were
more effective (i.e., total QALYs) than Pap annually. The
combination annually strategy saves 0.69 days of discounted
QALY per woman compared with Pap annually. Whereas total
costs of the combination strategy is more than 1.4-fold (combina-
tion every 5 years) to 2.0-fold (combination annually) that of the
annual Pap strategy (NT$4242) (Table 3). Thus, extending the
cervical cancer screening interval from Pap annually to HPV-Pap
strategy every 3 or 5 years can be considered.
Second, differences in cost structures may account the difference
between cost-effectiveness results in this study and those obtained
by other studies using the HPV DNA testing as primary screening
or combined with Pap smear for cervical cancer screening. The
unit cost of the HPV DNA testing is 40% more than that of a Pap
smear in Taiwan. Conversely, the unit cost of the HPV DNA testing
is roughly identical to that of Pap smear in many European
countries and in the United States (Mandelblatt et al, 2002b; Kim
et al, 2004, 2005; Bistoletti et al, 2008). In comparison, the
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sscreening cost of the HPV-Pap and combination strategies are
higher in Taiwan than in other countries.
Third, using the HPV DNA testing increased disease cases by
detecting more precancerous lesions than Pap smear alone
(Naucler et al, 2009). The costs of treatment with the HPV-Pap
or combination strategy may be lower than Pap smear alone
theoretically. In fact, the costs of treatments for precancerous
lesions and cervical cancer in Taiwan are lower than those in many
countries (Goldie et al, 2004; Kim et al, 2004, 2005; Tang et al,
2010). For instance, treatment cost was roughly NT$6956 for
CIN II or III patients. These figures are more than three-fold in the
UK (US$678, about NT$22463) and seven-fold in the United States
(US$2833, about NT$93863). Moreover, overall invasive cervical
cancer treatment costs are 1.6-fold higher in the Netherlands
(US$17603, about NT$583223) to 2.8-fold higher in the UK
(US$31494, about NT$1043443) than in Taiwan (NT$375322).
The difference in treatment cost between the HPV-Pap or
combination strategy and Pap smear alone is less in Taiwan than
that in other countries. Consequently, using the HPV DNA testing
has the potential to improve health effectiveness at a reasonable
cost compared with the Pap smear in European countries and in
the United States is not surprising. Early detection of precancerous
lesions may not reduce treatment costs largely; thus, it may have
difficulty being cost-effective when treatment costs are generally
lower in Taiwan than in other countries.
Analytical results demonstrated that extending screening intervals
from Pap annually to every 3 or 5 years would save costs but be less
effective; this finding is generally consistent with those in studies by
Anderson et al (2008) and Siebert et al (2006). The population of
women aged X30 years, that is, those targeted for cervical cancer
screening, was estimated at approximately 7 million in Taiwan in
2008 (Directorate-General of Budget, Accounting and Statistics,
2009b). However, the budget for the screening program (free annual
Pap smear-approximately NT$430 for one Pap smear) from the
Bureau of Health Promotion, Department of Health, was only
NT$860 million annually (Liberty Times, 2009). Although this figure
seems quite small, it hardly meets the expenses under low
participation. As a result of the limited resources available for
cervical cancer screening programs, implementing an annual
screening program is barely affordable. The cost-effectiveness results
obtained by this study suggest that HPV-Pap every 3 or 5 years
represent an optimal use of resources, considering improve
participation rate and extending screening intervals.
Some studies have explored factors associated with low
participation for the cervical cancer screening program in Taiwan
(Lee et al, 1997; Lin et al, 2003, 2007). These factors may be
summarised as Taiwanese women having a more lax attitude
toward cervical cancer screening programs, perhaps because of
societal values or those in traditional culture. This is also at play in
the difficulty policy-makers have faced during the last decade in
determining how to improve coverage for Pap smear screening.
One alternative to screening may be self-sampling, which may
make cervical cancer screening more accessible to women not
participating in the current screening program or those rarely
contacting health-care centres, offering an important method for
increasing cervical cancer screening coverage (Sellors et al, 2000;
Wright et al, 2000; Agorastos et al, 2005; De Alba et al, 2008).
Future studies should evaluate the cost-effectiveness of self-
sampling for HPV DNA testing.
This study has several limitations. First, women treated for CIN I,
CIN II or III may have a different (i.e., higher or lower) probability of
recurrent cervical lesions than those who have negative test results.
However, we did not have good evidence on this difference. Thus, we
assumed that women treated for CIN I, CIN II or III were cured and
returned to a normal state and acquired a new HPV infection at
similar rates to those without previous abnormal results. The model
assumed that women must have been infected with HPV to develop
further lesions or diseases. This study did not consider disease
progression without previous HPV infection.
Second, while the natural history model was based on Taiwan
calibrated data sources from studies, most transition probabilities
were obtained from literature with no age stratification for all Pap,
HPV-Pap, and combination strategies. The model also used the
same cervical cancer survival rate for all ages, which is not the case
in reality. This may add to model uncertainties and parameter
uncertainties in analytical results; however, sensitivity analyses
demonstrate the robustness of study results.
Third, this study did not consider women age o30 years who have
already infected with high-risk HPV. According to a cohort study in
Taiwan, the prevalence of HPV infection was 9.09% in women age
o30 years (Huang et al, 2008). For women with HPV infection, they
are recommended to undergo a Pap smear as a triage screening. If
necessary, further tests or treatments will be required. Thus, the total
costs estimates in this study may have been underestimated;
however, the magnitude is not likely to be high.
Finally, this study also assumed that all women with negative
primary screening results were asked to undergo regular screening
until 69 years of age. Although the recent scientific evidence
suggests that women aged 50 or above with negative HPV test
results will have a lower risk to develop cervical cancer, it is the
general consensus in Taiwan that aged women should also be
covered in screening programs. It will be of value, however, to
explore the cost-effectiveness of polices that considered the
strategies for different age groups.
In conclusion, this study demonstrates that, compared with a
no-screening or an annual Pap strategy, using the HPV DNA
testing in the cervical screening program in Taiwan is cost-
effective. This study also identified as cost-effective for extending
the cervical cancer screening interval from Pap annually to HPV-
Pap strategy every 3 or 5 years had ICERs of NT$1303000 or
NT$1247000 per QALY gained, respectively. Considering the
potential economic advantages, HPV-Pap strategy every 5 years
would seem to be more attractive, especially in Taiwan, a country
with a publicly financed health-care system.
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